262 related articles for article (PubMed ID: 22317852)
21. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
22. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.
Yamasaki Y; Yamada H; Yamasaki M; Ohkubo M; Azuma K; Matsuoka S; Kurihara Y; Osada H; Satoh M; Ozaki S
Rheumatology (Oxford); 2007 Jan; 46(1):124-30. PubMed ID: 16754626
[TBL] [Abstract][Full Text] [Related]
23. Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?
Abignano G; Bissell LA; Emery P; Del Galdo F; Buch MH
Rheumatology (Oxford); 2016 Dec; 55(12):2273-2275. PubMed ID: 27744357
[No Abstract] [Full Text] [Related]
24. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
[TBL] [Abstract][Full Text] [Related]
25. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide in scleroderma lung disease.
Kuschner WG
N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726
[No Abstract] [Full Text] [Related]
27. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
[TBL] [Abstract][Full Text] [Related]
33. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.
Dheda K; Lalloo UG; Cassim B; Mody GM
Clin Rheumatol; 2004 Aug; 23(4):306-9. PubMed ID: 15293090
[TBL] [Abstract][Full Text] [Related]
34. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.
Schnabel A; Reuter M; Gross WL
Arthritis Rheum; 1998 Jul; 41(7):1215-20. PubMed ID: 9663478
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
36. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
[TBL] [Abstract][Full Text] [Related]
37. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
Yamano Y; Taniguchi H; Kondoh Y; Ando M; Kataoka K; Furukawa T; Johkoh T; Fukuoka J; Sakamoto K; Hasegawa Y
Respirology; 2018 Nov; 23(11):1041-1048. PubMed ID: 30011421
[TBL] [Abstract][Full Text] [Related]
38. Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.
Takahashi T; Asano Y; Sunaga R; Ichimura Y; Taniguchi T; Yamamoto M; Tamaki Z; Takekoshi T; Mitsui H; Sugaya M; Ohse T; Sato S
J Dermatol; 2014 Jun; 41(6):533-5. PubMed ID: 24814462
[TBL] [Abstract][Full Text] [Related]
39. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease.
Yiannopoulos G; Pastromas V; Antonopoulos I; Katsiberis G; Kalliolias G; Liossis SN; Andonopoulos AP
Rheumatol Int; 2007 Feb; 27(4):357-61. PubMed ID: 17021713
[TBL] [Abstract][Full Text] [Related]
40. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
